IPSC Stock Forecast: Century Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.17
−11.74% on the day

The median 12-month analyst price target for Century Therapeutics, Inc. is $4.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$211.6M
Ticker Nerd rank
44/ 100
Median analyst target
$4.50
Analysts covering
5
Revenue$0.0
Operating income−$25.4M
Net income−$34.5M
Free cash flow−$20.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.4%
1M
−29.0%
YTD
+17.1%
1Y
+137.3%
From 52W high
−60.4%
From 52W low
+137.8%
$0.49
$2.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
89
Revisions
58
Quality
53
Accruals
48
Issuance
45
Value
37
Volatility
16
Growth
13

Momentum (89): The shares have been drifting up relative to others.

Growth (13): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IPSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26IPSCHigh $8.00Median $4.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4
Buy
1
Hold
0
Sell
$2.00
Low
$4.50
Median
$8.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 May 2026MizuhoInitiatesOutperform$8.00
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
17 Nov 2025Leerink PartnersDowngradeMarket Perform—
16 May 2025Chardan CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025GuggenheimReiteratesBuy—
24 Mar 2025Chardan CapitalMaintainsBuy—
21 Mar 2025GuggenheimMaintainsBuy—
20 Mar 2025Piper SandlerMaintainsOverweight—
22 Jan 2025GuggenheimReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
30 Dec 2024Piper SandlerMaintainsOverweight—
7 Nov 2024Chardan CapitalMaintainsBuy—
6 Nov 2024HC Wainwright & Co.MaintainsBuy—
15 Aug 2024HC Wainwright & Co.MaintainsBuy—
17 June 2024Piper SandlerMaintainsOverweight—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.MaintainsBuy—
12 Apr 2024Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IPSC.

Market Radar

This page is one stock. Monday covers all of them.

IPSC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IPSC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Century Therapeutics, Inc. returned +137.3% against +6.9% for the S&P 500, dividends included.

IPSC vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600Jan 26Apr 26Jul 26Oct 26IPSCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IPSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.9×

Cheaper than 49% of US stocks

Price / book
1.0×

Cheaper than 71% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−9.6%

Higher than 26% of US stocks

Net margin
—
Returns & dividend
Return on equity
−51.2%

Higher than 21% of US stocks

Return on assets
−25.5%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Century Therapeutics, Inc. has a market value of $211.6M and an enterprise value of $131.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$109.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$88.1M.

  • Shares outstanding: 180.5M.

  • Century Therapeutics, Inc. employs 78 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

IPSC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IPSCCentury Therapeutics, Inc.$211.6M44
ALLOAllogene Therapeutics, Inc.$207.9M45
RCKTRocket Pharmaceuticals, Inc.$211.0M36
ARCTArcturus Therapeutics Holdings, Inc.$211.7M74
DTILPrecision BioSciences, Inc.$204.3M81
VNDAVanda Pharmaceuticals, Inc.$203.6M72
FTHFaeth Therapeutics, Inc.$203.1M26

Take a look at IPSC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IPSC

What is the IPSC stock price forecast for 2026-2027?

The median 12-month analyst price target for Century Therapeutics, Inc. is $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IPSC stock a buy right now?

Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IPSC?

As at 21 Nov 2026, Century Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).

Will IPSC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $4.5, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IPSC stock forecast for 2030?

No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has IPSC stock performed over the past year?

Century Therapeutics, Inc. returned +137.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Century Therapeutics, Inc. do?

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies.

Company

About Century Therapeutics, Inc.

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies. Its current pipeline also includes programs in type 1 diabetes and other autoimmune applications, reflecting a broader effort to apply engineered cell therapy platforms across multiple disease areas. Century Therapeutics combines stem cell derivation, gene editing, and immune-evasion technologies to support scalable manufacturing and differentiated product development. Headquartered in Philadelphia, Pennsylvania, Century Therapeutics operates in the advanced biotechnology segment of the healthcare market, where it develops next-generation cellular medicines intended for clinical use.

CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com